Reference health
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV
29/29 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
2 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 29 checked references that resolve
resolves10.1200/JCO.2010.32.0598
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
resolves10.1200/JCO.2013.49.9020
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
resolves10.1056/NEJMoa1002315
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
resolves10.1182/blood-2011-08-376087
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
resolves10.1182/blood-2013-06-511592
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
resolves10.1038/leu.2012.134
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
resolves10.1182/blood-2013-05-501569
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
resolves10.1371/journal.pone.0076013
Comorbid Diseases Interact with Breast Cancer to Affect Mortality in the First Year after Diagnosis—A Danish Nationwide Matched Cohort Study
resolves10.3324/haematol.2013.096792
Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials
resolves10.1016/0021-9681(87)90171-8
A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
resolves10.1016/j.leukres.2009.02.005
Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes
resolves10.3324/haematol.2011.048991
Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes
resolves10.1586/17474086.2013.837279
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors
resolves10.3324/haematol.2011.041251
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib
resolves10.1002/ajh.23330
Long‐term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study
resolves10.1182/blood-2009-08-237115
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
resolves10.1182/blood-2006-02-005686
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
resolves10.1200/JCO.2009.25.0779
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
resolves10.1182/blood-2010-12-319038
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
resolves10.1182/blood-2006-01-0092
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
resolves10.1038/leu.2012.104
Standardized definitions of molecular response in chronic myeloid leukemia
resolves10.1002/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO;2-Q
Evaluation of patients with advanced cancer using the karnofsky performance status
resolves10.1038/leu.2011.116
Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia
resolves10.1007/s00277-013-1937-4
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV
resolves10.1182/blood.V124.21.153.153
Survival and Prognosis in Patients with First-Line Imatinib Treatment Under Particular Consideration of Death Due to Chronic Myeloid Leukemia
resolves10.1038/leu.2008.245
Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany
The 2 references without a DOI — listed, not checked
no DOI — not checkedSafety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV [published online ahead of print February 13, 2015].
no DOI — not checked2019111901382979900_B29
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1182/blood-2015-01-617993"><img src="https://citestamp.com/citestamped/10.1182/blood-2015-01-617993/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1182/blood-2015-01-617993)